The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Transcatheter heart valve thrombosis on the mitral stage: “The Tempest” or “Much Ado About Nothing”?

EuroIntervention 2021;16:1386-1387. DOI: 10.4244/EIJV16I17A253

1. Heart Valve Center, NYU Langone Health, New York, NY, USA


The description of subclinical leaflet thrombosis following transcatheter aortic valve implantation (TAVI) created great drama and controversy for the field because of a potential association with cerebral embolic disease1; however, subsequent systematic studies have alleviated such concerns2,3. Transcatheter mitral valve implantation (TMVI) (using a balloon-expandable transcatheter SAPIEN prosthesis [Edwards Lifesciences, Irvine, CA, USA]) is a highly effective, minimally invasive treatment for degenerated mitral bioprostheses, but may also be applied to native leaflet failure in the presence of a surgical mitral ring or mitral annular calcification (MAC)4. Studies with dedicated prostheses are continuing for TMVI in native mitral valves in ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Lipid-lowering therapy and percutaneous coronary interventions

Latest news